Does the patient have osteoporosis based on the Dual Energy X-ray Absorptiometry (DXA) scan results?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Does This Patient Have Osteoporosis?

No, this patient does not have osteoporosis—the diagnosis is osteopenia (low bone mass). The lowest T-score is -2.2 at the left total hip, which falls in the osteopenic range (T-score between -1.0 and -2.5), not the osteoporotic range (T-score ≤ -2.5) 1, 2.

Diagnostic Criteria Applied

The diagnosis is based on the lowest T-score from any measured site, which in this case is -2.2 at the left total proximal femur 1, 2. According to WHO classification:

  • Normal bone density: T-score ≥ -1.0 1, 2
  • Osteopenia (low bone mass): T-score between -1.0 and -2.5 1, 2
  • Osteoporosis: T-score ≤ -2.5 1, 2
  • Severe osteoporosis: T-score ≤ -2.5 plus one or more fragility fractures 3

Review of All Measured Sites

The T-scores at each anatomic site confirm osteopenia without reaching the osteoporosis threshold 1:

  • Left femoral neck: -1.7 (osteopenia) 1
  • Right femoral neck: -1.5 (osteopenia) 1
  • Left total hip: -2.2 (osteopenia, lowest score) 1
  • Right total hip: -1.9 (osteopenia) 1
  • Lumbar spine L1-L4: -1.1 (osteopenia) 1

Important Clinical Context

This patient has multiple significant risk factors for osteoporosis that warrant close monitoring and potential treatment consideration 1:

  • Rheumatoid arthritis: A recognized medical condition that adversely affects BMD 1
  • Family history: Relative with hip fracture increases fracture risk 1
  • Significant weight loss: 65 pounds lost, which can accelerate bone loss 1
  • Methotrexate use: Long-term medication known to adversely affect BMD 1

The FRAX score shows 12% 10-year probability of major osteoporotic fracture and 0.7% hip fracture risk, which are relatively low but should be interpreted in context of the patient's rheumatoid arthritis 1, 2.

Positive Finding: Significant BMD Improvement

The comparison to the previous scan shows substantial increases in BMD at all sites 1:

  • Right hip: 8.1% increase 1
  • Right femoral neck: 27.7% increase 1
  • Left hip: 8% increase 1
  • Left femoral neck: 23.4% increase 1
  • Lumbar spine: 13.7% increase 1

These improvements exceed the least significant change thresholds reported for this facility, indicating real bone density gains rather than measurement variability 1, 2.

Treatment Considerations Despite Osteopenia Diagnosis

Although this patient does not meet the T-score criterion for osteoporosis, treatment should be strongly considered based on the following algorithm 1, 2:

High-Risk Features Present:

  • Rheumatoid arthritis is an established secondary cause of osteoporosis requiring evaluation 1
  • T-score approaching -2.5 at the left total hip (-2.2) 1
  • Multiple risk factors including family history and significant weight loss 1

Treatment Decision Framework:

The American College of Physicians recommends making treatment decisions for osteopenic patients based on fracture risk profile, patient preferences, and medication benefits/harms 1. For this patient:

  • Continue current vitamin D supplementation 1
  • Ensure adequate calcium intake (>1000 mg/day) 4
  • Consider pharmacologic treatment given rheumatoid arthritis and borderline T-score 1
  • Discuss bisphosphonates or denosumab as first-line options if treatment is pursued 3

Monitoring Recommendations

Follow-up DXA scanning should occur in 2 years given the patient's risk factors and rheumatoid arthritis, rather than the typical 2-3 year interval 1. For patients with inflammatory arthritides or those on medications affecting BMD, annual or biennial monitoring is appropriate 1.

Important caveat: BMD should not be measured at the radius in patients with rheumatoid arthritis due to local juxta-articular bone loss that results in falsely low readings 1.

Secondary Causes Evaluation

The report correctly notes that secondary causes for bone loss should be evaluated, as the etiology of low BMD cannot be determined by BMD measurement alone 1. Given this patient's rheumatoid arthritis and methotrexate use, the low bone density is likely multifactorial 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

DXA Scan Interpretation Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Osteoporosis: Common Questions and Answers.

American family physician, 2023

Guideline

Treatment for Osteoporosis in Young Adults with Cerebral Palsy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.